Last reviewed · How we verify
Tavapadon tablet
At a glance
| Generic name | Tavapadon tablet |
|---|---|
| Sponsor | Cerevel Therapeutics, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Expanded Access to Tavapadon
- Open-label Trial in Parkinson's Disease (PD) (PHASE3)
- Flexible-Dose Trial in Early Parkinson's Disease (PD) (PHASE3)
- Fixed-Dose Trial in Early Parkinson's Disease (PD) (PHASE3)
- A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants (PHASE1)
- Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) (PHASE3)
- To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function (PHASE1)
- Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |